Yıl: 2019 Cilt: 36 Sayı: 3 Sayfa Aralığı: 141 - 147 Metin Dili: İngilizce DOI: 10.5152/NSN.2019.10324 İndeks Tarihi: 06-07-2020

Examination of IL-1β level as an inflammasome marker in Alzheimer's disease

Öz:
Objective: Interleukin (IL)-1β is believed to be responsible for the neurotoxicity of amyloid plaques in Alzheimer’s disease (AD). In the present study, serum levels of IL-1β, and correlations with clinical features and neuropsychiatric test results were examined.Methods: Thirty-eight patients with AD and 38 healthy control patients were included in the study. Serum IL-1β levels in pa-tients with AD and control were analyzed using enzyme-linked immunosorbent assay method. The Mini-Mental Test Score (MMSE) and Geriatric Depression Scale (GDS) were administered to both the patient and control groups. Furthermore, the clin-ical dementia rating, detailed neuropsychological test battery, and neuropsychiatric inventory were administered to the AD group. It was determined that the serum IL-1β measurements of the patient and control groups were not statistically different, and IL-1β measurements in the patient group were not correlated with the MMSE and GDS.Results: The relationship of IL-1β measurements in the patient group with other clinical data was not significant. Among the patients' neuropsychological tests, a moderately, significant negative correlation was found only between the clock drawing test and visual learning score and serum IL-1β levels.Conclusion: Our study is in agreement with other studies in which no significant difference was found between patients with AD and healthy controls in terms of serum IL-1β levels, but the moderately negative correlation obtained with the clock drawing test and visual learning score indicates a weak relation. This result may indicate that stronger relations will be determined in large-scale studies involving larger numbers of patients.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Dickson DW. The pathogenesis of senile plaques. J Neuropathol Exp Neurol 1997; 56: 321-339. [CrossRef]
  • 2. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzhei-mer's disease. Neurobiol Aging 2000; 21: 383-421. [CrossRef] 3. Wegiel J, Wang KC, Imaki H, et al. The role of microglial cells and astrocytes in fibrillar plaque evolution in transgenic APP(SW) mice. Neurobiol Aging 2001; 22: 49-61. [CrossRef] 4. Halle A, Hornung V, Petzold GC, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 2008; 9: 857-865. [CrossRef] 5. Griffin WS, Stanley LC, Ling C, et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A 1989; 86: 7611-7615. [CrossRef]
  • 6. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011; 117: 3720-3732. [CrossRef]
  • 7. Webb AC, Collins KL, Auron PE, et al. Interleukin-1 gene (IL1) as-signed to long arm of human chromosome 2. Lymphokine Res 1986; 5: 77-85.
  • 8. Güngen C, Ertan T, Eker E, Yaşar R, Engin F. Reliability and validi-ty of the standardized Mini Mental State Examination in the di-agnosis of mild dementia in Turkish population. Turk Psikiyatri Derg 2002; 13: 273-281.
  • 9. Öktem Tanör Ö. Öktem Sözel Bellek Süreçleri Testi (Öktem-VMPT) El Kitabı. Türk Psikologlar Derneği Yayınları, 2011, No: 34, Ankara.
  • 10. Wechsler D. Manual for the Wechsler Memory Scale-Revised, The Psychological Corporation, 1987, San Antonio, TX. 11. Tumaç A. The effect of age and education on performance in some frontal damage-susceptible tests in normal subjects. İs-tanbul Üniversitesi, Sosyal Bilimler Enstitüsü, Unpublished mas-ter's thesis, 1997.
  • 12. Öktem Tanör Ö. Nöropsikolojik Değerlendirme In: Tanrıdağ O, Davranış Nörolojisi, Nobel Tıp Kitabevleri, 2016, İstanbul. 13. Shulman KI, Gold DP, Cohen CA, Zucchero CA. Clock-drawing and dementia in the community: A longitudinal study. Int J Geri-atr Psychiatry 1993; 8: 487-496. [CrossRef] 14. Fernández-Blázquez MA, Ruiz-Sánchez de León JM, López-Pina JA, Llanero-Luque M, Montenegro-Peña M, Montejo-Carrasco P. A new shortened version of the Boston Naming Test for those aged over 65: an approach from item response theory. Rev Neu-rol 2012; 55: 399-407. [CrossRef]
  • 15. Ertan T, Eker E. Reliability, validity, and factor structure of the geriatric depression scale in Turkish elderly: are there different factor structures for different cultures? Int Psychogeriatr 2000; 12: 163-172. [CrossRef] 16. Griffin WS, Stanley LC, Ling C, et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A 1989; 86: 7611-7615. [CrossRef] 17. Mrak RE, Sheng JG, Griffin WS. Correlation of astrocytic S100 beta expression with dystrophic neurites in amyloid plaques of Alzheimer's disease. J Neuropathol Exp Neurol 1996; 55: 273-279. [CrossRef] 18. Moynagh PN, Williams DC, O'Neill LA. Activation of NF-kappa B and induction of vascular cell adhesion molecule-1 and intracel-lular adhesion molecule-1 expression in human glial cells by IL-1. Modulation by antioxidants. J Immunol 1994; 153: 2681-2690.
  • 19. Rosenman SJ, Shrikant P, Dubb L, Benveniste EN, Ransohoff RM. Cytokine-induced expression of vascular cell adhesion mole-cule-1 (VCAM-1) by astrocytes and astrocytoma cell lines. J Im-munol 1995; 154: 1888-1899. 20. Lee KS, Chung JH, Choi TK, Suh SY, Oh BH, Hong CH. Peripheral cytokines and chemokines in Alzheimer's disease. Dement Geri-atr Cogn Disord 2009; 28: 281-287. [CrossRef]
  • 21. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis 2010; 37: 13-25. [CrossRef] 22. Marques F, Sousa JC, Sousa N, Palha JA. Blood-brain-barriers in aging and in Alzheimer's disease. Mol Neurodegener 2013; 8: 38. [CrossRef]
  • 23. Montagne A, Barnes SR, Sweeney MD, et al. Blood-brain barrier breakdown in the aging human hippocampus. Neuron 2015; 85: 296-302. [CrossRef] 24. Licastro F, Pedrini S, Caputo L, et al. Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? J Neuroimmunol 2000; 103: 97-102. [CrossRef]
  • 25. Zuliani G, Ranzini M, Guerra G, et al. Plasma cytokines profile in older subjects with late onset Alzheimer's disease or vascular dementia. J Psychiatr Res 2007; 41: 686-693. [CrossRef]
  • 26. Forlenza OV, Diniz BS, Talib LL, et al. Increased serum IL-1beta level in Alzheimer's disease and mild cognitive impairment. De-ment Geriatr Cogn Disord 2009; 28: 507-512. [CrossRef]
  • 27. Tarkowski E, Andreasen N, Tarkowski A, Blennow K. Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2003; 74: 1200-1205. [CrossRef]
  • 28. Galimberti D, Schoonenboom N, Scheltens P, et al. Intrathecal chemokine synthesis in mild cognitive impairment and Alzhei-mer disease. Arch Neurol 2006; 63: 538-543. [CrossRef]
  • 29. Magaki S, Mueller C, Dickson C, Kirsch W. Increased production of inflammatory cytokines in mild cognitive impairment. Exp Gerontol 2007; 42: 233-240. [CrossRef] 30. Lanzrein AS, Johnston CM, Perry VH, Jobst KA, King EM, Smith AD. Longitudinal study of inflammatory factors in serum, ce-rebrospinal fluid, and brain tissue in Alzheimer disease: inter-leukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin. Alzheimer Dis 147 Assoc Disord 1998; 12: 215-227. [CrossRef]
  • 31. Alvarez XA, Franco A, Fernández-Novoa L, Cacabelos R. Blood levels of histamine, IL-1 beta, and TNF-alpha in patients with mild to moderate Alzheimer disease. Mol Chem Neuropathol 1996; 29: 237-252. [CrossRef] 32. Khemka VK, Ganguly A, Bagchi D, et al. Raised serum proinflam-matory cytokines in Alzheimer's disease with depression. Aging Dis 2014; 5: 170-176. [CrossRef] 33. Oztürk C, Ozge A, Yalin OO, et al. The diagnostic role of serum inflammatory and soluble proteins on dementia subtypes: cor-relation with cognitive and functional decline. Behav Neurol 2007; 18: 207-215. [CrossRef] 34. Dursun E, Gezen-Ak D, Hanağası H, et al. The interleukin 1 alpha, interleukin 1 beta, interleukin 6 and alpha-2-macroglobulin se-rum levels in patients with early or late onset Alzheimer's dis-ease, mild cognitive impairment or Parkinson's disease. J Neuro-immunol 2015; 283: 50-57. [CrossRef]
  • 35. De Luigi A, Fragiacomo C, Lucca U, Quadri P, Tettamanti M, Gra-zia De Simoni M. Inflammatory markers in Alzheimer's disease and multi-infarct dementia. Mech Ageing Dev 2001; 122: 1985-1995. [CrossRef] 36. Yasutake C, Kuroda K, Yanagawa T, Okamura T, Yoneda H. Serum BDNF, TNF-alpha and IL-1beta levels in dementia patients: com-parison between Alzheimer's disease and vascular dementia. Eur Arch Psychiatry Clin Neurosci 2006; 256: 402-406. [CrossRef]
  • 37. Corsi MM, Licastro F, Porcellini E, et al. Reduced plasma levels of P-selectin and L-selectin in a pilot study from Alzheimer disease: relationship with neuro-degeneration. Biogerontology 2011; 12: 451-454. [CrossRef]
  • 38. Pirttila T, Mehta PD, Frey H, Wisniewski HM. Alpha 1-antichymo-trypsin and IL-1 beta are not increased in CSF or serum in Alzhei-mer's disease. Neurobiol Aging 1994; 15: 313-317. [CrossRef]
  • 39. Angelopoulos P, Agouridaki H, Vaiopoulos H, et al. Cytokines in Alzheimer's disease and vascular dementia. Int J Neurosci 2008;118: 1659-1672. [CrossRef]
  • 40. Zhou X, Fragala MS, McElhaney JE, Kuchel GA. Conceptual and methodological issues relevant to cytokine and inflammatory marker measurements in clinical research. Curr Opin Clin Nutr Metab Care 2010; 13: 541-547. [CrossRef]
APA Bulut O, Tanburoğlu A, BÖLÜK G, demir n, EREN E, VURGUN U, Genc S, Yener G (2019). Examination of IL-1β level as an inflammasome marker in Alzheimer's disease. , 141 - 147. 10.5152/NSN.2019.10324
Chicago Bulut Onur,Tanburoğlu Anıl,BÖLÜK Gülşah,demir nurhak,EREN Erden,VURGUN Ufuk,Genc Sermin,Yener Görsev G. Examination of IL-1β level as an inflammasome marker in Alzheimer's disease. (2019): 141 - 147. 10.5152/NSN.2019.10324
MLA Bulut Onur,Tanburoğlu Anıl,BÖLÜK Gülşah,demir nurhak,EREN Erden,VURGUN Ufuk,Genc Sermin,Yener Görsev G. Examination of IL-1β level as an inflammasome marker in Alzheimer's disease. , 2019, ss.141 - 147. 10.5152/NSN.2019.10324
AMA Bulut O,Tanburoğlu A,BÖLÜK G,demir n,EREN E,VURGUN U,Genc S,Yener G Examination of IL-1β level as an inflammasome marker in Alzheimer's disease. . 2019; 141 - 147. 10.5152/NSN.2019.10324
Vancouver Bulut O,Tanburoğlu A,BÖLÜK G,demir n,EREN E,VURGUN U,Genc S,Yener G Examination of IL-1β level as an inflammasome marker in Alzheimer's disease. . 2019; 141 - 147. 10.5152/NSN.2019.10324
IEEE Bulut O,Tanburoğlu A,BÖLÜK G,demir n,EREN E,VURGUN U,Genc S,Yener G "Examination of IL-1β level as an inflammasome marker in Alzheimer's disease." , ss.141 - 147, 2019. 10.5152/NSN.2019.10324
ISNAD Bulut, Onur vd. "Examination of IL-1β level as an inflammasome marker in Alzheimer's disease". (2019), 141-147. https://doi.org/10.5152/NSN.2019.10324
APA Bulut O, Tanburoğlu A, BÖLÜK G, demir n, EREN E, VURGUN U, Genc S, Yener G (2019). Examination of IL-1β level as an inflammasome marker in Alzheimer's disease. Neurological sciences and neurophysiology (Online), 36(3), 141 - 147. 10.5152/NSN.2019.10324
Chicago Bulut Onur,Tanburoğlu Anıl,BÖLÜK Gülşah,demir nurhak,EREN Erden,VURGUN Ufuk,Genc Sermin,Yener Görsev G. Examination of IL-1β level as an inflammasome marker in Alzheimer's disease. Neurological sciences and neurophysiology (Online) 36, no.3 (2019): 141 - 147. 10.5152/NSN.2019.10324
MLA Bulut Onur,Tanburoğlu Anıl,BÖLÜK Gülşah,demir nurhak,EREN Erden,VURGUN Ufuk,Genc Sermin,Yener Görsev G. Examination of IL-1β level as an inflammasome marker in Alzheimer's disease. Neurological sciences and neurophysiology (Online), vol.36, no.3, 2019, ss.141 - 147. 10.5152/NSN.2019.10324
AMA Bulut O,Tanburoğlu A,BÖLÜK G,demir n,EREN E,VURGUN U,Genc S,Yener G Examination of IL-1β level as an inflammasome marker in Alzheimer's disease. Neurological sciences and neurophysiology (Online). 2019; 36(3): 141 - 147. 10.5152/NSN.2019.10324
Vancouver Bulut O,Tanburoğlu A,BÖLÜK G,demir n,EREN E,VURGUN U,Genc S,Yener G Examination of IL-1β level as an inflammasome marker in Alzheimer's disease. Neurological sciences and neurophysiology (Online). 2019; 36(3): 141 - 147. 10.5152/NSN.2019.10324
IEEE Bulut O,Tanburoğlu A,BÖLÜK G,demir n,EREN E,VURGUN U,Genc S,Yener G "Examination of IL-1β level as an inflammasome marker in Alzheimer's disease." Neurological sciences and neurophysiology (Online), 36, ss.141 - 147, 2019. 10.5152/NSN.2019.10324
ISNAD Bulut, Onur vd. "Examination of IL-1β level as an inflammasome marker in Alzheimer's disease". Neurological sciences and neurophysiology (Online) 36/3 (2019), 141-147. https://doi.org/10.5152/NSN.2019.10324